Recent advances in scleroderma-associated pulmonary hypertension

Area of Science:

• Rheumatology
• Pulmonology
• Cardiology

Background:

• Pulmonary hypertension (PH) is a significant cause of morbidity and mortality in patients with scleroderma (SSc).
• Pulmonary arterial hypertension (PAH), specifically WHO Group I, is the most common form, but other WHO groups of PH can also occur in SSc.
• PAH is now recognized as a diagnostic criterion for SSc.

Purpose of the Study:

• To review recent advancements in understanding and managing pulmonary hypertension in scleroderma.
• To highlight new insights into the epidemiology, pathogenesis, and clinical risk factors of SSc-associated PH.
• To discuss updated recommendations for the evaluation, screening, and goal-directed therapy of SSc-PH.

Main Methods:

• Literature review of recent research on SSc-pulmonary hypertension.
• Analysis of epidemiological data, including prevalence, incidence, and risk factors.
• Synthesis of current understanding of pathogenesis, particularly the role of inflammation.

Main Results:

• Enhanced understanding of SSc-PH epidemiology and risk factors.
• Greater insight into the inflammatory pathways involved in SSc-PAH pathogenesis.
• Improved methods for evaluation and screening, leading to earlier detection and better survival outcomes.
• Development of evidence-based recommendations for goal-directed therapy.

Conclusions:

• Significant progress has been made in managing SSc-pulmonary hypertension.
• Early detection and tailored therapy improve survival for SSc-PH patients.
• Further research is essential to develop preventative strategies and cures for this life-threatening condition.